Freeman Chris sold $10.8M of GH
Freeman Chris (Chief Commercial Officer) sold 63,605 shares of Guardant Health, Inc. (GH) at an average of $169.58 ($167.38–$170.24, $10.79M total) across 4 trades on 2026-08-10.
How this was made
The 30-second read
Why it matters
A Chief Commercial Officer’s multi-tranche open-market sale totaling ~$10.79M can affect short-term sentiment, but it is not a corporate action or operating update.
Market read
Traders may monitor for subsequent insider activity or any company-specific catalysts, but this filing alone is unlikely to drive a durable repricing.
What to watch
The filing does not state a 10b5-1 plan, but it also does not provide the insider’s rationale; without follow-on buying or guidance changes, fundamental impact is uncertain.
Background
The article is a SEC Form 4 insider transaction disclosure for Guardant Health, Inc.
Ticker impact
Guardant Health Form 4 shows CCO Freeman Chris sold 63,605 shares in open-market trades for about $10.79M at ~$169.58 average.
Near-term price impact is likely limited, but it can add short-term overhang or raise questions about insider conviction.
Form 4 insider sales can be routine and do not confirm negative fundamentals; however, the size and absence of a stated 10b5-1 plan can influence sentiment and trading flows.
Market effects
No direct sector read-through beyond general sentiment around biotech/healthcare insider activity.
None indicated.
None indicated.
Counterpoint
The sale may be unrelated to company outlook (taxes, diversification, planned liquidity needs), so it should not be treated as a strong bearish signal.
Key entities
- issuerGuardant Health, Inc.
Public company whose insider transaction is disclosed on Form 4.
- insiderFreeman Chris
Chief Commercial Officer who sold 63,605 shares across four trades on Aug 10.
